Since the completion of the ToGA study in 2014, the combination of human epidermal growth factor receptor 2 (HER2) inhibitors and chemotherapy has become the standard treatment for advanced gastric cancer patients with HER2 amplification, prolonging the overall survival (OS) to 13.8 months [5–7]. The gene discussed is ERBB2; the disease is gastric cancer.